{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T17:32:54Z","timestamp":1773077574980,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2007,6,15]],"date-time":"2007-06-15T00:00:00Z","timestamp":1181865600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1038\/sj.eye.6702906","type":"journal-article","created":{"date-parts":[[2007,6,16]],"date-time":"2007-06-16T12:45:10Z","timestamp":1181997910000},"page":"1391-1397","source":"Crossref","is-referenced-by-count":18,"title":["Twenty-four-hour efficacy of the brimonidine\/timolol fixed combination versus therapy with the unfixed components"],"prefix":"10.1038","volume":"22","author":[{"given":"A G P","family":"Konstas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I E","family":"Katsimpris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Kaltsos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"Georgiadou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Kordelou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L A","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W C","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,6,15]]},"reference":[{"key":"BF6702906_CR1","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1089\/jop.2005.21.337","volume":"21","author":"ER Craven","year":"2005","unstructured":"Craven ER, Walters TR, Williams R, Chou C, Cheetham JK, Schiffman R et al. Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther 2005; 21: 337\u2013348.","journal-title":"J Ocul Pharmacol Ther"},{"key":"BF6702906_CR2","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1001\/archopht.124.9.1230","volume":"124","author":"MB Sherwood","year":"2006","unstructured":"Sherwood MB, Craven ER, Chou C, DuBiner HB, Batoosingh AL, Schiffman RM et al. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch Ophthalmol 2006; 124: 1230\u20131238.","journal-title":"Arch Ophthalmol"},{"key":"BF6702906_CR3","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1177\/112067210501500508","volume":"15","author":"FJ Goni","year":"2005","unstructured":"Goni FJ, Brimonidine\/Timolol Fixed Combination Study Group. 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension. Eur J Ophthalmol 2005; 15: 581\u2013590.","journal-title":"Eur J Ophthalmol"},{"key":"BF6702906_CR4","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1097\/00061198-200004000-00002","volume":"9","author":"S Asrani","year":"2000","unstructured":"Asrani S, Zeimer R, Wilensky J, Gieser D, Vitale S, Lindenmuth K . Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma 2000; 9: 134\u2013142.","journal-title":"J Glaucoma"},{"key":"BF6702906_CR5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1001\/archopht.122.1.29","volume":"122","author":"AG Konstas","year":"2004","unstructured":"Konstas AG, Hollo G, Astakhov YS, Teus MA, Akopov EL, Jenkins JN et al. Factors associated with long-term progression or stability in exfoliation glaucoma. Arch Ophthalmol 2004; 122: 29\u201333.","journal-title":"Arch Ophthalmol"},{"key":"BF6702906_CR6","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/S0002-9394(02)01460-5","volume":"133","author":"AG Konstas","year":"2002","unstructured":"Konstas AG, Nakos E, Tersis I, Lallos NA, Leech JN, Stewart WC . A comparison of once-daily morning vs evening dosing of concomitant latanoprost\/timolol. Am J Ophthalmol 2002; 133: 753\u2013757.","journal-title":"Am J Ophthalmol"},{"key":"BF6702906_CR7","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/S0161-6420(03)00404-4","volume":"110","author":"AG Konstas","year":"2003","unstructured":"Konstas AG, Papapanos P, Tersis I, Houliara D, Stewart WC . Twenty-four-hour diurnal curve comparison of commercially available latanoprost 0.005% versus the timolol and dorzolamide fixed combination. Ophthalmology 2003; 110: 1357\u20131360.","journal-title":"Ophthalmology"},{"key":"BF6702906_CR8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/sj.eye.6700257","volume":"17","author":"AG Konstas","year":"2003","unstructured":"Konstas AG, Kozobolis VP, Tersis I, Leech J, Stewart WC . The efficacy and safety of the timolol\/dorzolamide fixed combination vs latanoprost in exfoliation glaucoma. Eye 2003; 17: 41\u201346.","journal-title":"Eye"},{"key":"BF6702906_CR9","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0002-9394(01)00834-0","volume":"131","author":"AG Konstas","year":"2001","unstructured":"Konstas AG, Stewart WC, Topouzis F, Tersis I, Holmes KT, Stangos NT . Brimonidine 0.2% given two or three times daily versus timolol maleate 0.5% in primary open-angle glaucoma. Am J Ophthalmol 2001; 131: 729\u2013733.","journal-title":"Am J Ophthalmol"},{"key":"BF6702906_CR10","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/eye.2001.14","volume":"15","author":"AG Konstas","year":"2001","unstructured":"Konstas AG, Lake S, Maltezos AC, Holmes KT, Stewart WC . 24 hour intraocular pressure reduction with latanoprost compared with pilocarpine as third-line therapy in exfoliation glaucoma. Eye 2001; 15: 59\u201362.","journal-title":"Eye"},{"key":"BF6702906_CR11","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/eye.2000.16","volume":"14","author":"AG Konstas","year":"2000","unstructured":"Konstas AG, Maltezos A, Bufidis T, Hudgins AG, Stewart WC . Twenty-four hour control of intraocular pressure with dorzolamide and timolol maleate in exfoliation and primary open-angle glaucoma. Eye 2000; 14: 73\u201377.","journal-title":"Eye"},{"key":"BF6702906_CR12","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.ophtha.2004.08.022","volume":"112","author":"AG Konstas","year":"2005","unstructured":"Konstas AG, Katsimbris JM, Lallos N, Boukaras GP, Jenkins JN, Stewart WC . Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients. Ophthalmology 2005; 112: 262\u2013266.","journal-title":"Ophthalmology"},{"key":"BF6702906_CR13","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/S0002-9394(00)00930-2","volume":"131","author":"WC Stewart","year":"2001","unstructured":"Stewart WC, Holmes KT, Johnson MA . Washout periods for brimonidine 0.2% and latanoprost 0.005%. Am J Ophthalmol 2001; 131: 798\u2013799.","journal-title":"Am J Ophthalmol"},{"key":"BF6702906_CR14","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1001\/archopht.121.4.453","volume":"121","author":"N Orzalesi","year":"2003","unstructured":"Orzalesi N, Rossetti L, Bottoli A, Fumagalli E, Fogagnolo P . Effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Arch Ophthalmol 2003; 121: 453\u2013457.","journal-title":"Arch Ophthalmol"},{"key":"BF6702906_CR15","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1001\/archopht.1997.01100150184006","volume":"115","author":"AG Konstas","year":"1997","unstructured":"Konstas AG, Mantziris DA, Stewart WC . Diurnal intraocular pressure in untreated exfoliation and primary open-angle glaucoma. Arch Ophthalmol 1997; 115: 182\u2013185.","journal-title":"Arch Ophthalmol"},{"key":"BF6702906_CR16","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1001\/archopht.1997.01100160145002","volume":"115","author":"AG Konstas","year":"1997","unstructured":"Konstas AG, Mantziris DA, Cate EA, Stewart WC . Effect of timolol on the diurnal intraocular pressure in exfoliation and primary open-angle glaucoma. Arch Ophthalmol 1997; 115: 975\u2013979.","journal-title":"Arch Ophthalmol"},{"key":"BF6702906_CR17","unstructured":"Book SA . Essentials of Statistics. McGraw-Hill: New York, 1978; 117\u2013122."},{"key":"BF6702906_CR18","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1089\/jop.1998.14.129","volume":"14","author":"TK Mundorf","year":"1998","unstructured":"Mundorf TK, Cate EA, Sine CS, Otero DW, Stewart JA, Stewart WC . Safety and efficacy of switching timolol maleate 0.5% solution to timolol hemihydrate 0.5% solution given twice daily. J Ocul Pharmacol Ther 1998; 14: 129\u2013135.","journal-title":"J Ocul Pharmacol Ther"},{"key":"BF6702906_CR19","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1111\/j.1755-3768.1987.tb07052.x","volume":"65","author":"GR Duff","year":"1987","unstructured":"Duff GR . A double-masked crossover study comparing the effects of carteolol 1% and 2% on intra-ocular pressure. Acta Ophthalmol (Copenh) 1987; 65: 618\u2013621.","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"BF6702906_CR20","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S0002-9394(00)00902-8","volume":"131","author":"WC Stewart","year":"2001","unstructured":"Stewart WC, Day DG, Stewart JA, Schuhr J, Latham KE . The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001; 131: 631\u2013635.","journal-title":"Am J Ophthalmol"},{"key":"BF6702906_CR21","unstructured":"Siegel S . Nonparametric Statistics for the Behavioral Sciences. McGraw Hill: New York, 1956; 63\u201367."},{"key":"BF6702906_CR22","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1016\/S0161-6420(98)91045-4","volume":"105","author":"K Strohmaier","year":"1998","unstructured":"Strohmaier K, Snyder E, DuBiner H, Adamsons I . The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Dorzolamide-Timolol Study Group. Ophthalmology 1998; 105: 1936\u20131944.","journal-title":"Ophthalmology"},{"key":"BF6702906_CR23","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/bjo.2003.018234","volume":"88","author":"M Diestelhorst","year":"2004","unstructured":"Diestelhorst M, Larsson LI, European Latanoprost Fixed Combination Study Group. A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension. Br J Ophthalmol 2004; 88: 199\u2013203.","journal-title":"Br J Ophthalmol"},{"key":"BF6702906_CR24","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ophtha.2005.06.027","volume":"113","author":"M Diestelhorst","year":"2006","unstructured":"Diestelhorst M, Larsson LI, European-Canadian Latanoprost Fixed Combination Study Group. A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components. Ophthalmology 2006; 113: 70\u201376.","journal-title":"Ophthalmology"},{"key":"BF6702906_CR25","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.ajo.2005.02.058","volume":"140","author":"JS Schuman","year":"2005","unstructured":"Schuman JS, Katz GJ, Lewis RA, Henry JC, Mallick S, Wells DT et al. Efficacy and safety of a fixed combination of travoprost 0.004%\/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2005; 140: 242\u2013250.","journal-title":"Am J Ophthalmol"},{"key":"BF6702906_CR26","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1097\/01.ijg.0000176935.08392.14","volume":"14","author":"BA Hughes","year":"2005","unstructured":"Hughes BA, Bacharach J, Craven ER, Kaback MB, Mallick S, Landry TA et al. A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%\/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension. J Glaucoma 2005; 14: 392\u2013399.","journal-title":"J Glaucoma"},{"key":"BF6702906_CR27","first-page":"10","volume":"106","author":"JE Boyle","year":"1999","unstructured":"Boyle JE, Ghosh K, Gieser DK, Adamsons IA . A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol or dorzolamide. Ophthalmology 1999; 106: 10\u201316.","journal-title":"Ophthalmology"},{"key":"BF6702906_CR28","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1046\/j.1600-0420.2004.0205.x","volume":"82","author":"RD Fechtner","year":"2004","unstructured":"Fechtner RD, Airaksinen PJ, Getson AJ, Lines CR, Adamsons IA, COSOPT versus XALATAN Study Groups. Efficacy and tolerability of the dorzolamide 2%\/timolol 0.5% combination (Cosopt) versus 0.005% (Xalatan) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials. Acta Ophthalmol Scand 2004; 82: 42\u201348.","journal-title":"Acta Ophthalmol Scand"},{"key":"BF6702906_CR29","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.ophtha.2003.05.019","volume":"111","author":"DH Shin","year":"2004","unstructured":"Shin DH, Feldman RM, Sheu WP, Fixed Combination Latanoprost\/Timolol Study Group. Efficacy and safety of the fixed combinations latanoprost\/timolol versus dorzolamide\/timolol in patients with elevated intraocular pressure. Ophthalmology 2004; 111: 276\u2013282.","journal-title":"Ophthalmology"},{"key":"BF6702906_CR30","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s00417-002-0553-0","volume":"240","author":"N Pfeiffer","year":"2002","unstructured":"Pfeiffer N, German Latanoprost Fixed Combination Study Group. A comparison of the fixed combination of latanoprost and timolol with its individual components. Graefes Arch Clin Exp Ophthalmol 2002; 240: 893\u2013899.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"BF6702906_CR31","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1001\/archopht.120.7.915","volume":"120","author":"EJ Higginbotham","year":"2002","unstructured":"Higginbotham EJ, Feldman R, Stiles M, Dubiner H . Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial. Arch Ophthalmol 2002; 120: 915\u2013922.","journal-title":"Arch Ophthalmol"},{"key":"BF6702906_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajo.2005.02.043","volume":"140","author":"HS Barnebey","year":"2005","unstructured":"Barnebey HS, Orengo-Nania S, Flowers BE, Samples J, Mallick S, Landry TA et al. The safety and efficacy of travoprost 0.004%\/timolol 0.5% fixed combination ophthalmic solution. Am J Ophthalmol 2005; 140: 1\u20137.","journal-title":"Am J Ophthalmol"},{"key":"BF6702906_CR33","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1177\/112067210601600308","volume":"16","author":"P Denis","year":"2006","unstructured":"Denis P, Andrew R, Wells D, Friren B . A comparison of morning and evening instillation of a combination travoprost 0.004%\/timolol 0.5% ophthalmic solution. Eur J Ophthalmol 2006; 16: 407\u2013415.","journal-title":"Eur J Ophthalmol"},{"key":"BF6702906_CR34","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/jps.2600630304","volume":"63","author":"SS Chrai","year":"1974","unstructured":"Chrai SS, Makoid MC, Eriksen SP, Robinson JR . Drop size and initial dosing frequency problems of topically applied ophthalmic drugs. J Pharm Sci 1974; 63: 333\u2013338.","journal-title":"J Pharm Sci"},{"key":"BF6702906_CR35","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/0002-9394(86)90939-6","volume":"101","author":"MA Kass","year":"1986","unstructured":"Kass MA, Meltzer DW, Gordon M, Cooper D, Goldberg J . Compliance with topical pilocarpine treatment. Am J Ophthalmol 1986; 101: 515\u2013523.","journal-title":"Am J Ophthalmol"},{"key":"BF6702906_CR36","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1136\/bjo.66.7.464","volume":"66","author":"PA Granstr\u00f6m","year":"1982","unstructured":"Granstr\u00f6m PA . Glaucoma patients not compliant with their drug therapy: clinical and behavioral aspects. Br J Ophthalmol 1982; 66: 464\u2013470.","journal-title":"Br J Ophthalmol"},{"key":"BF6702906_CR37","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1136\/bjo.61.8.531","volume":"61","author":"S Bloch","year":"1977","unstructured":"Bloch S, Rosenthal AR, Friedman L, Caldarolla P . Patient compliance in glaucoma. Br J Ophthalmol 1977; 61: 531\u2013534.","journal-title":"Br J Ophthalmol"},{"key":"BF6702906_CR38","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1089\/jop.2004.20.461","volume":"20","author":"WC Stewart","year":"2004","unstructured":"Stewart WC, Konstas AG, Pfeiffer N . Patient and ophthalmologist attitudes concerning compliance and dosing in glaucoma treatment. J Ocul Pharmacol Ther 2004; 20: 461\u2013469.","journal-title":"J Ocul Pharmacol Ther"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6702906.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6702906","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6702906.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:30:31Z","timestamp":1684413031000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6702906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,15]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["BF6702906"],"URL":"https:\/\/doi.org\/10.1038\/sj.eye.6702906","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6,15]]}}}